CN1395576A - (-)-顺式-2-(2-氯苯基)-5,7-二羟基-8-[4r-(3s-羟基-1-甲基)哌啶基]-4h-1-苯并吡喃-4-酮的假多晶 - Google Patents
(-)-顺式-2-(2-氯苯基)-5,7-二羟基-8-[4r-(3s-羟基-1-甲基)哌啶基]-4h-1-苯并吡喃-4-酮的假多晶 Download PDFInfo
- Publication number
- CN1395576A CN1395576A CN01803847A CN01803847A CN1395576A CN 1395576 A CN1395576 A CN 1395576A CN 01803847 A CN01803847 A CN 01803847A CN 01803847 A CN01803847 A CN 01803847A CN 1395576 A CN1395576 A CN 1395576A
- Authority
- CN
- China
- Prior art keywords
- medium
- flavopiridol
- contain
- space
- relative intensity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Stereophonic System (AREA)
- Inorganic Insulating Materials (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
2θ角(°) | D空间- | 相对强度 | 相对强度(%) |
6.95020.52915.83016.56024.77826.45721.09126.22625.89818.3208.30823.74813.01030.52027.10631.15329.04314.60019.033 | 12.7084.3235.5945.3493.5903.3664.2093.3953.4384.83910.6343.7446.7992.9273.2872.8693.0726.0624.659 | 强强强中等中等中等中等中等中等中等中等中等中等中等弱弱弱弱弱 | 100.075.958.549.546.642.040.739.538.837.135.733.432.431.026.222.423.722.420.6 |
2θ角(°) | D空间- | 相对强度(%) |
6.92013.85027.9086.66920.8387.33931.66010.20814.72216.41325.829 | 12.7636.3893.19413.2444.25912.0362.8248.6596.0125.3973.447 | 100.035.722.218.013.813.89.58.37.26.96.5 |
Claims (24)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48471700A | 2000-01-18 | 2000-01-18 | |
US09/484,717 | 2000-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1395576A true CN1395576A (zh) | 2003-02-05 |
CN1174977C CN1174977C (zh) | 2004-11-10 |
Family
ID=23925305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018038476A Expired - Lifetime CN1174977C (zh) | 2000-01-18 | 2001-01-08 | (-)-顺式-2-(2-氯苯基)-5,7-二羟基-8-[4r-(3s-羟基-1-甲基)哌啶基]-4h-1-苯并吡喃-4-酮的假多晶 |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1259507B1 (zh) |
JP (1) | JP2003520797A (zh) |
KR (1) | KR100806464B1 (zh) |
CN (1) | CN1174977C (zh) |
AT (1) | ATE273303T1 (zh) |
AU (1) | AU2001226346A1 (zh) |
BR (1) | BR0107726A (zh) |
CA (1) | CA2397593C (zh) |
CZ (1) | CZ301195B6 (zh) |
DE (1) | DE60104822T2 (zh) |
DK (1) | DK1259507T3 (zh) |
EA (1) | EA005247B1 (zh) |
ES (1) | ES2222332T3 (zh) |
HU (1) | HUP0204126A3 (zh) |
IL (2) | IL150638A0 (zh) |
MX (1) | MXPA02007005A (zh) |
NO (1) | NO322572B1 (zh) |
NZ (1) | NZ520280A (zh) |
PL (1) | PL200696B1 (zh) |
PT (1) | PT1259507E (zh) |
SI (1) | SI1259507T1 (zh) |
SK (1) | SK287404B6 (zh) |
TR (1) | TR200402036T4 (zh) |
TW (1) | TWI284129B (zh) |
WO (1) | WO2001053293A1 (zh) |
ZA (1) | ZA200205639B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190175598A1 (en) | 2016-08-23 | 2019-06-13 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
MX2019010981A (es) | 2017-03-16 | 2020-09-07 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de cancer de mama. |
AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164232B (zh) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
US5908934A (en) * | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
-
2001
- 2001-01-08 NZ NZ520280A patent/NZ520280A/en not_active IP Right Cessation
- 2001-01-08 KR KR1020027009215A patent/KR100806464B1/ko active IP Right Grant
- 2001-01-08 CN CNB018038476A patent/CN1174977C/zh not_active Expired - Lifetime
- 2001-01-08 SK SK1036-2002A patent/SK287404B6/sk not_active IP Right Cessation
- 2001-01-08 AT AT01900939T patent/ATE273303T1/de active
- 2001-01-08 DE DE60104822T patent/DE60104822T2/de not_active Expired - Lifetime
- 2001-01-08 DK DK01900939T patent/DK1259507T3/da active
- 2001-01-08 EP EP01900939A patent/EP1259507B1/en not_active Expired - Lifetime
- 2001-01-08 WO PCT/US2001/000519 patent/WO2001053293A1/en active IP Right Grant
- 2001-01-08 IL IL15063801A patent/IL150638A0/xx unknown
- 2001-01-08 PL PL356165A patent/PL200696B1/pl unknown
- 2001-01-08 HU HU0204126A patent/HUP0204126A3/hu unknown
- 2001-01-08 CA CA002397593A patent/CA2397593C/en not_active Expired - Lifetime
- 2001-01-08 EA EA200200775A patent/EA005247B1/ru not_active IP Right Cessation
- 2001-01-08 TR TR2004/02036T patent/TR200402036T4/xx unknown
- 2001-01-08 PT PT01900939T patent/PT1259507E/pt unknown
- 2001-01-08 BR BR0107726-0A patent/BR0107726A/pt not_active Application Discontinuation
- 2001-01-08 SI SI200130201T patent/SI1259507T1/xx unknown
- 2001-01-08 ES ES01900939T patent/ES2222332T3/es not_active Expired - Lifetime
- 2001-01-08 JP JP2001553767A patent/JP2003520797A/ja active Pending
- 2001-01-08 MX MXPA02007005A patent/MXPA02007005A/es active IP Right Grant
- 2001-01-08 CZ CZ20022466A patent/CZ301195B6/cs not_active IP Right Cessation
- 2001-01-08 AU AU2001226346A patent/AU2001226346A1/en not_active Abandoned
- 2001-01-16 TW TW090100957A patent/TWI284129B/zh not_active IP Right Cessation
-
2002
- 2002-07-08 IL IL150638A patent/IL150638A/en active IP Right Grant
- 2002-07-12 NO NO20023386A patent/NO322572B1/no not_active IP Right Cessation
- 2002-07-15 ZA ZA200205639A patent/ZA200205639B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101470715B1 (ko) | 다사티닙 다결정체 및 그의 제조방법과 약물 조성물 | |
JP2023116645A (ja) | フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用 | |
CN107531678A (zh) | Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
JP2016183193A (ja) | フィダキソマイシンの固体状形態およびその調製方法 | |
RU2648990C1 (ru) | Кристаллы лобаплатина, способы получения и применения в фармацевтике | |
CN104540820A (zh) | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 | |
CN1174977C (zh) | (-)-顺式-2-(2-氯苯基)-5,7-二羟基-8-[4r-(3s-羟基-1-甲基)哌啶基]-4h-1-苯并吡喃-4-酮的假多晶 | |
KR20230038229A (ko) | 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도 | |
US6576647B2 (en) | Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one | |
RU2169150C2 (ru) | Получение цефотаксима и натриевая соль цефотаксима | |
CN103059013B (zh) | 达沙替尼一水合物的晶型及其制备方法 | |
TWI680983B (zh) | 一種鈉-葡萄糖共同轉運蛋白2抑制劑的l-脯胺酸複合物、其一水合物及晶體 | |
CN105777651A (zh) | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 | |
CN113840605A (zh) | N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式,及其制备方法和治疗用途 | |
CN111423441A (zh) | 一类具有抗肿瘤活性的卤代吲哚苦参碱衍生物及制备方法和应用 | |
EP3666767A1 (en) | Pyridazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof | |
AU2015247489B2 (en) | Polymorphic forms and co-crystals of a c-Met inhibitor | |
CN1395577A (zh) | (-)-顺-2-(2-氯苯基)-5,7-二羟基-8[4r-(3s-羟基-1-甲基)哌啶基]-4h-1-苯并吡喃-4-酮的乙醇溶剂化物 | |
Gessier et al. | Synthesis of Imidazolo‐Piperidinopentoses as Nagstatine Analogues | |
CN103880833B (zh) | 达沙替尼一水合物的新晶形及其制备方法和药物组合物 | |
CN106794179A (zh) | 马赛替尼甲磺酸盐的新晶型及其制备方法 | |
JP2023534552A (ja) | ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩及び結晶形 | |
CN105061273B (zh) | 酒石酸沃尼妙林多晶型及其制备方法 | |
CN109678803A (zh) | 一种新颖的4,6-二取代氨基嘧啶类jak激酶抑制剂的制备与应用 | |
WO2023081779A1 (en) | Crystalline forms of a diffusion enhancing compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: AVENTIS HOLDING CO.,LTD. Free format text: FORMER OWNER: ARWENDIE PHARMACY CORP. Effective date: 20090619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090619 Address after: Delaware Patentee after: Aventis holding company Address before: new jersey Patentee before: Aventis Pharmaceuticals Inc. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1052342 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: AVENTIS-SAAB CO.,LTD. Free format text: FORMER OWNER: AVENTIS HOLDING COMPANY Effective date: 20100525 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100525 Address after: Delaware Patentee after: Aventis Pharma Inc. Address before: Delaware Patentee before: Aventis holding company |
|
CX01 | Expiry of patent term |
Granted publication date: 20041110 |
|
CX01 | Expiry of patent term |